Beijing Bohui Innovation Biotechnology Group (300318.SZ) subsidiary Langfang Bohui terminates cooperation contract with Bioptech project.

Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced that its subsidiary, Langfang Bohui Biopharmaceutical Co., Ltd. ("Langfang Bohui"), signed a Project Cooperation Agreement with Chengdu Biotec Pharmacon Co., Ltd. ("Biotec Pharmacon") in January 2020 for the joint application of a freeze-dried human rabies vaccine (serum-free Vero cells) that Biotec Pharmacon had completed preclinical research on. In July 2020, the vaccine received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. In September 2024, Langfang Bohui, Biotec Pharmacon, and other related parties signed a Supplementary Agreement to the Project Cooperation Agreement, agreeing that upon meeting certain conditions, the Project Cooperation Agreement signed in January 2020 would be terminated, and the clinical trial of the freeze-dried human rabies vaccine (serum-free Vero cells) developed by both parties would be terminated. Recently, Langfang Bohui received the full compensation payment (18 million RMB) from Biotec Pharmacon, and the Project Cooperation Agreement has officially been terminated.